Verastem Inc (VSTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.03B
Last updated: Nov 17, 2026 at 11:05 AM ET
Verastem Inc (VSTM) Earnings: Report Dates and Results
Verastem (VSTM) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Verastem reported EPS of -$0.74, below the -$0.44 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VSTM has an expected report date of Mar 2, 2027.
VSTM Earnings Call
The latest VSTM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, VSTM beat 16, missed 22 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $24.01M, up 113.6% from $11.24M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.74 | -$0.44 | -$0.44 - -$0.44 | -68.18% | Miss | N/A | 2 | 0 up, 1 down | Nov 5, 2026 | $24.01M |
| Jun 30, 2026 | -$0.35 | -$0.46 | N/A | +23.91% | Beat | N/A | 3 | 1 up, 0 down | Aug 6, 2026 | $40.08M |
| Mar 31, 2026 | -$0.43 | -$0.47 | -$0.50 - -$0.44 | +8.51% | Beat | N/A | 3 | 1 up, 0 down | May 7, 2026 | $18.67M |
| Dec 31, 2025 | -$0.46 | -$0.50 | -$0.51 - -$0.47 | +7.55% | Beat | N/A | 3 | 1 up, 0 down | Mar 4, 2026 | $17.54M |
| Sep 30, 2025 | -$0.54 | -$0.61 | -$0.68 - -$0.56 | +11.48% | Beat | N/A | 3 | 1 up, 0 down | Nov 4, 2025 | $11.24M |
| Jun 30, 2025 | -$0.39 | -$0.59 | N/A | +33.90% | Beat | N/A | 2 | N/A | Aug 7, 2025 | $2.14M |
| Mar 31, 2025 | -$0.79 | -$0.77 | -$0.94 - -$0.61 | -2.60% | Miss | N/A | 2 | 1 up, 0 down | May 13, 2025 | N/A |
| Dec 31, 2024 | -$0.60 | -$0.74 | -$0.92 - -$0.53 | +18.56% | Beat | N/A | 3 | 0 up, 1 down | Mar 20, 2025 | N/A |
| Sep 30, 2024 | -$0.88 | -$0.82 | -$1.08 - -$0.65 | -7.32% | Miss | N/A | 9 | 0 up, 0 down | Nov 6, 2024 | N/A |
| Jun 30, 2024 | -$0.61 | -$1.06 | -$1.11 - -$0.65 | +42.45% | Beat | N/A | 7 | 1 up, 0 down | Aug 8, 2024 | $10.00M |
| Mar 31, 2024 | -$0.98 | -$0.87 | -$1.19 - -$0.87 | -12.64% | Miss | N/A | 5 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$1.02 | -$0.62 | -$0.88 - $0.43 | -64.52% | Miss | N/A | 7 | 0 up, 0 down | Mar 14, 2024 | $114000 |
| Sep 30, 2023 | -$0.71 | -$0.79 | -$1.22 - -$0.74 | +10.13% | Beat | N/A | 7 | 0 up, 0 down | Nov 8, 2023 | N/A |
| Jun 30, 2023 | -$1.15 | -$1.02 | -$1.20 - -$0.83 | -12.75% | Miss | N/A | 5 | 2 up, 0 down | Aug 8, 2023 | N/A |
| Mar 31, 2023 | -$1.14 | -$0.98 | -$1.08 - -$0.84 | -16.33% | Miss | N/A | 5 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | -$0.08 | -$0.10 | -$0.10 - -$0.09 | +20.00% | Beat | N/A | 5 | 0 up, 0 down | Mar 14, 2023 | $2.60M |
| Sep 30, 2022 | -$1.08 | -$1.47 | -$1.56 - -$1.44 | +26.53% | Beat | N/A | 6 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$1.44 | -$1.32 | N/A | -9.09% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | N/A |
| Mar 31, 2022 | -$1.08 | -$1.02 | -$1.20 - -$0.84 | -5.88% | Miss | N/A | 5 | 0 up, 1 down | May 9, 2022 | $2.60M |
| Dec 31, 2021 | -$0.09 | -$0.09 | -$0.12 - -$0.08 | 0.00% | In line | N/A | 4 | N/A | Mar 28, 2022 | $1.55M |
| Sep 30, 2021 | -$1.56 | -$0.84 | -$1.08 - -$0.84 | -85.71% | Miss | -262.5% | 4 | N/A | Nov 4, 2021 | $2000 |
| Jun 30, 2021 | -$1.20 | -$1.00 | -$1.08 - -$0.96 | -20.00% | Miss | N/A | 3 | N/A | Aug 2, 2021 | $500000 |
| Mar 31, 2021 | -$1.08 | -$1.08 | -$1.08 - -$1.08 | 0.00% | In line | N/A | 1 | N/A | May 11, 2021 | N/A |
| Dec 31, 2020 | -$0.12 | -$0.08 | -$0.11 - -$0.06 | -50.00% | Miss | N/A | 2 | N/A | Mar 18, 2021 | $506000 |
| Sep 30, 2020 | $0.96 | $0.52 | -$0.96 - $3.36 | +84.62% | Beat | N/A | 3 | N/A | Nov 9, 2020 | $78.65M |
| Jun 30, 2020 | -$1.68 | -$1.76 | -$2.16 - -$1.32 | +4.55% | Beat | N/A | 3 | N/A | Aug 10, 2020 | $4.31M |
| Mar 31, 2020 | -$4.20 | -$2.58 | -$3.36 - -$2.16 | -62.79% | Miss | N/A | 4 | N/A | May 7, 2020 | $5.06M |
| Dec 31, 2019 | -$0.51 | -$0.45 | -$0.65 - -$0.33 | -13.33% | Miss | N/A | 4 | N/A | Mar 11, 2020 | $3.62M |
| Sep 30, 2019 | -$4.20 | -$4.92 | -$6.36 - -$4.92 | +14.63% | Beat | N/A | 4 | N/A | Oct 29, 2019 | $9.03M |
| Jun 30, 2019 | -$5.76 | -$5.84 | -$6.72 - -$5.76 | +1.37% | Beat | N/A | 5 | N/A | Aug 1, 2019 | $3.14M |
| Mar 31, 2019 | -$6.24 | -$5.64 | -$6.00 - -$5.04 | -10.64% | Miss | N/A | 6 | N/A | May 9, 2019 | $1.67M |
| Dec 31, 2018 | -$0.49 | -$0.53 | -$0.79 - -$0.34 | +7.55% | Beat | N/A | 6 | N/A | Mar 12, 2019 | $1.21M |
| Sep 30, 2018 | -$5.97 | -$4.68 | -$6.12 - -$4.68 | -27.56% | Miss | N/A | 7 | N/A | Nov 7, 2018 | $15.51M |
| Jun 30, 2018 | -$5.56 | -$4.30 | -$4.80 - -$2.64 | -29.30% | Miss | N/A | 8 | N/A | Aug 8, 2018 | $10.00M |
| Mar 31, 2018 | -$0.41 | -$0.39 | -$0.50 - -$0.36 | -5.13% | Miss | N/A | 6 | N/A | May 3, 2018 | N/A |
| Dec 31, 2017 | -$5.16 | -$5.10 | -$6.72 - -$4.08 | -1.18% | Miss | N/A | 6 | N/A | Mar 13, 2018 | N/A |
| Sep 30, 2017 | -$7.32 | -$3.96 | N/A | -84.85% | Miss | N/A | N/A | N/A | Nov 7, 2017 | N/A |
| Jun 30, 2017 | -$4.32 | -$3.96 | N/A | -9.09% | Miss | N/A | N/A | N/A | Aug 8, 2017 | N/A |
| Mar 31, 2017 | -$4.20 | -$4.32 | N/A | +2.78% | Beat | N/A | N/A | N/A | May 10, 2017 | N/A |
| Dec 31, 2016 | -$0.32 | -$0.25 | N/A | -28.00% | Miss | N/A | N/A | N/A | Mar 23, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.18, after -$3.07 the year before. It was -$5.82 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.18 | N/A |
| Dec 31, 2024 | -$3.07 | N/A |
| Dec 31, 2023 | -$4.02 | N/A |
| Dec 31, 2022 | -$3.68 | N/A |
| Dec 31, 2021 | -$3.93 | N/A |
| Dec 31, 2020 | -$5.04 | N/A |
| Dec 31, 2019 | -$16.71 | N/A |
| Dec 31, 2018 | -$12.43 | N/A |
| Dec 31, 2017 | -$21.00 | N/A |
| Dec 31, 2016 | -$5.82 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,703 | 15 | |
| 2026Q2 | Jun 30, 2026 | 5,210 | 14 | |
| 2026Q1 | Mar 31, 2026 | 7,981 | 14 | |
| 2025Q4 | Dec 31, 2025 | 7,122 | 13 | |
| 2025Q3 | Sep 30, 2025 | 4,835 | 12 | |
| 2025Q2 | Jun 30, 2025 | 6,471 | 15 |
2026Q3 Earnings Call
Opening remarks
Julissa Viana Senior Vice President of Corporate Communications, Investor Relations and Patient Advocacy Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss Verastem's Third Quarter 2026 financial results and recent business updates. This afternoon, we issued a press release detailing these results, along with the slide presentation that we will reference during our call today. Both are available on the Investor Relations section of our website. Before we begin, let me point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today, we'll be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. Joining me on today's call to deliver prepared remarks and take your questions are Dan Paterson, President and Chief Executive Officer; Dan Lyons, Chief Commercial Officer; Dr. Michael D. Kauffman, President of Development; and lastly, Dan Calkins, Chief Financial Officer. I will now turn the call over to Dan.
Daniel Paterson President and Chief Executive Officer Thank you, Julissa. Good afternoon, and thank you for joining our call today. We're encouraged by the progress we've made across our commercial business and the VS-7375 development program. We generated net product revenue of $24 million in the third quarter, with demand holding steady for AVMAPKI FAKZYNJA CO-PACK and strong refills offsetting new patient starts after significant growth in Q2. As Dan Lyons will discuss, we feel that there's still considerable opportunity to be realized for the CO-PACK. While we continue to see a positive impact from the changes we've made throughout the commercial organization, we're making additional efforts to gather feedback from physicians to understand patient experiences and educate on new and existing initiatives. We're also excited to share that our new blister pack NDA has been accepted by the FDA with priority review and a PDUFA date of February 2027. This is an important step we are taking to further support patient convenience and adherence to the CO-PACK. Turning to the VS-7375 program. In October, we announced new clinical data from our TARGET-D 101 trial, including, for the first time, U.S. efficacy data and updated safety and tolerability results in KRAS G12D-mutated pancreatic, colorectal and lung cancers. As Michael Kauffman will discuss in more detail, we set a new efficacy benchmark in pancreatic cancer with compelling and confirmed response rates across lines of therapy, and we demonstrated encouraging antitumor activity in both colorectal and non-small cell lung cancers. With longer follow-up, VS-7375 continued to demonstrate a favorable and manageable safety profile at both the 600- and 900-milligram dose levels.
Frequently Asked Questions About VSTM
When is Verastem's next earnings date?
Verastem's next earnings report is expected for Mar 2, 2027.
Did VSTM beat earnings estimates last quarter?
No. Verastem reported EPS of -$0.74 for the quarter ended Sep 30, 2026, below the -$0.44 estimate by 68.18%.
What EPS do analysts expect from VSTM next quarter?
The consensus EPS estimate for Verastem for the quarter ending Dec 31, 2026 is -$0.50 from 12 analysts, with estimates from -$0.70 to -$0.36.
How often does VSTM beat earnings estimates?
Verastem beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +4.14%.
VSTM pages: Overview, Earnings, Forecast, Financials, Competitors